Takotsubo syndrome associated with structural brain alterations of the limbic system
Clinical trials have established the proof-of-concept for intrathecal ASO therapy, exemplified by tofersen for SOD1-ALS, which achieved accelerated approval based on biomarker reduction despite not meeting the primary clinical endpoint in its phase 3 VALOR trial (8, 43, 44)
If you experience any combination of these symptoms, particularly if you have risk factors, it is important to seek medical assessment promptly
Mehta AK, Arora N, Gaur SN, Singh BP: Choline supplementation reduces oxidative stress in mouse model of allergic airway disease
CNS Drugs 26 , 613636 (2012) Xiong, Y., Mahmood, A
Nature Medicine, 9 (10), 12691274